John Colombo1, D Jill Shaddy2, Kathleen Gustafson3, Byron J Gajewski4, Jocelynn M Thodosoff2, Elizabeth Kerling2, Susan E Carlson2. 1. Department of Psychology and Schiefelbusch Institute for Life Span Studies, University of Kansas, Lawrence, KS. 2. Department of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, KS. 3. Hoglund Brain Imaging Center, University of Kansas Medical Center, Kansas City, KS. 4. Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS.
Abstract
BACKGROUND:Docosahexaenoic acid (DHA) is a long-chain polyunsaturated fatty acid that has been linked to improved vision and cognition in postnatal feeding studies and has been consistently associated with reduction of early preterm birth in prenatal supplementation trials. This is a report of the first long-term follow-up of infants from mothers receivingprenatal DHA supplementation in a US cohort. OBJECTIVE: Our objective was to evaluate the efficacy of the prenatal supplementation on both global and granular longitudinal assessments of cognitive and behavioral development. METHODS: In a randomized double-blind clinical trial, mothers received either 600 mg/d of DHA or a placebo beginning at 14.5 weeks of gestation and capsules were provided until delivery. Children from those pregnancies were followed by cognitive and behavioral assessments administered from 10 mo through 6 y of age. From 301 mothers in the initial study, ∼200 infants completed the longitudinal schedule. RESULTS: Although this intervention had been shown to reduce high-risk pregnancies and improve visual attention in infants during the first year, only a few positive long-term effects of prenatal DHA supplementation emerged from analyses of this follow-up. Increases in maternal blood DHA during pregnancy were related to verbal and full scale intelligence quotient (IQ) scores at 5 and 6 y, but these effects disappeared after controlling for SES. Maternal blood DHA concentrations at delivery were unrelated to outcomes, although maternal DHA at enrollment was related to productive vocabulary at 18 mo. CONCLUSIONS: Although prenatal DHA supplementation substantially reduced early preterm birth and improved visual attention in infancy in this sample, no consistent long-term benefits were observed into childhood. Increases in maternal blood DHA concentration in pregnancy were related to higher IQs but this effect was confounded with SES and disappeared when SES was statistically controlled. This trial was registered at http://www.clinicaltrials.gov as NCT00266825 and NCT02487771.
RCT Entities:
BACKGROUND:Docosahexaenoic acid (DHA) is a long-chain polyunsaturated fatty acid that has been linked to improved vision and cognition in postnatal feeding studies and has been consistently associated with reduction of early preterm birth in prenatal supplementation trials. This is a report of the first long-term follow-up of infants from mothers receiving prenatal DHA supplementation in a US cohort. OBJECTIVE: Our objective was to evaluate the efficacy of the prenatal supplementation on both global and granular longitudinal assessments of cognitive and behavioral development. METHODS: In a randomized double-blind clinical trial, mothers received either 600 mg/d of DHA or a placebo beginning at 14.5 weeks of gestation and capsules were provided until delivery. Children from those pregnancies were followed by cognitive and behavioral assessments administered from 10 mo through 6 y of age. From 301 mothers in the initial study, ∼200 infants completed the longitudinal schedule. RESULTS: Although this intervention had been shown to reduce high-risk pregnancies and improve visual attention in infants during the first year, only a few positive long-term effects of prenatal DHA supplementation emerged from analyses of this follow-up. Increases in maternal blood DHA during pregnancy were related to verbal and full scale intelligence quotient (IQ) scores at 5 and 6 y, but these effects disappeared after controlling for SES. Maternal blood DHA concentrations at delivery were unrelated to outcomes, although maternal DHA at enrollment was related to productive vocabulary at 18 mo. CONCLUSIONS: Although prenatal DHA supplementation substantially reduced early preterm birth and improved visual attention in infancy in this sample, no consistent long-term benefits were observed into childhood. Increases in maternal blood DHA concentration in pregnancy were related to higher IQs but this effect was confounded with SES and disappeared when SES was statistically controlled. This trial was registered at http://www.clinicaltrials.gov as NCT00266825 and NCT02487771.
Authors: I S M van der Wurff; E C Bakker; G Hornstra; P A Kirschner; M Gielen; R W L Godschalk; S Kremers; M P Zeegers; R H M de Groot Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2016-03-26 Impact factor: 4.006
Authors: Mijna Hadders-Algra; Hylco Bouwstra; Saskia A van Goor; D A Janneke Dijck-Brouwer; Frits A J Muskiet Journal: J Perinat Med Date: 2007 Impact factor: 1.901
Authors: Julie E H Nevins; Sharon M Donovan; Linda Snetselaar; Kathryn G Dewey; Rachel Novotny; Jamie Stang; Elsie M Taveras; Ronald E Kleinman; Regan L Bailey; Ramkripa Raghavan; Sara R Scinto-Madonich; Sudha Venkatramanan; Gisela Butera; Nancy Terry; Jean Altman; Meghan Adler; Julie E Obbagy; Eve E Stoody; Janet de Jesus Journal: J Nutr Date: 2021-11-02 Impact factor: 4.687
Authors: Kathleen M Gustafson; Ke Liao; Nicole B Mathis; D Jill Shaddy; Elizabeth H Kerling; Danielle N Christifano; John Colombo; Susan E Carlson Journal: Nutr Neurosci Date: 2020-01-20 Impact factor: 4.994
Authors: Samaneh Ghasemi Fard; Su Peng Loh; Giovanni M Turchini; Bo Wang; Glenn Elliott; Andrew J Sinclair Journal: Nutrients Date: 2020-01-18 Impact factor: 5.717